Before revision: Trilaciclib , a CDK4/6 inhibitor under development by G1 Therapeutics, administered before chemotherapy in small cell lung cancer, has in three clinical trials been shown to reduce bone marrow suppression and the need for supportive care interventions.
After revision: Trilaciclib , a CDK4/6 inhibitor marketed(brand name Cosela) by G1 Therapeutics, administered before chemotherapy in small cell lung cancer, has in three clinical trials been shown to reduce bone marrow suppression and the need for supportive care interventions.